Question to the Ministry of Justice:

To ask the Secretary of State for Justice, how many people received custodial sentences for personal possession of cannabis excluding people imprisoned for intent to supply, production, or importation in each of the last ten years.

Answered by Nicholas Dakin - Government Whip, Lord Commissioner of HM Treasury

The Ministry of Justice publishes data on the number of offenders who received custodial sentences for possession of cannabis in the Outcomes by Offence tool: December 2023.

This can be accessed by navigating to the ‘Sentence Outcomes’ tab and using the ‘Sentence Outcome’ filter to select immediate custody and the ‘HO Offence Code’ filter to select the following HO offence codes:

09261 - Having possession of a controlled drug - class B (cannabis, including cannabis resin, cannabinol and cannabinol derivatives)

09266 - Having possession of a controlled drug - class C (cannabis, including cannabis resin, cannabinol and cannabinol derivatives) – historic

Offence groups and offence types are continually revised to reflect offences accurately. However, it is important to note that data have been extracted from large administrative data systems generated by the courts. As a consequence, offences that have been repealed may still be used by court administration and appear in the data.

Question to the Ministry of Justice:

To ask the Secretary of State for Justice, how many and what proportion of people who were convicted for simple cannabis possession were also convicted for another offence by the category of that other offence in each of the last five years.

Answered by Nicholas Dakin - Government Whip, Lord Commissioner of HM Treasury

The Ministry of Justice publishes data on the total number of convictions for possession of cannabis on all-offence basis in the All-offence prosecutions and convictions data tool.

A breakdown on how many offenders convicted for possession of cannabis were also convicted for another offence, and where an offender has been convicted of multiple counts of possession of cannabis at the same time, will count each individual conviction. Therefore, the information requested, on a defendant basis has been provided in Table 1 and Table 2.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will undertake a review of NHS policy on the assessment of individual funding requests to support children for whom prescribing medical cannabis could help prevent repeated admissions to hospital.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) has published technology appraisals recommending Epidyolex, a licensed form of cannabidiol extracted from cannabis, for the treatment of seizures associated with two rare forms of epilepsies, specifically Dravet syndrome and Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Deciding whether to prescribe an unlicensed cannabis-based medicine, a medicine that has not been assessed or approved by the medicines regulator, is a clinical decision, and the funding of medicines within the National Health Service is governed by well-established processes and evidence-based guidelines produced by the NICE. The NICE found that there is insufficient evidence of safety and effectiveness to support a population-wide recommendation in relation to unlicensed cannabis-based medicines for severe treatment-resistant epilepsy. The NICE also calls for further research.

Following the publication of the NICE’s guidance, NHS England and The National Institute for Health and Care Research (NIHR) has agreed funding for two trials relating to the use of cannabis-based medicines for the treatment of difficult-to-treat epilepsies. These will be world-first trials and will be crucial in informing future NHS funding decisions. Due to commercial confidentiality, further information on the trials cannot be released at this time.

Where a treatment is not currently routinely funded by the NHS in England, an NHS clinician can, on behalf of their patient, make an application for funding in exceptional clinical circumstances. This is known as an Individual Funding Request (IFR). In making an application for an IFR, clinicians must demonstrate that the patient in question is clinically exceptional compared to the wider group of patients with the same condition, and is likely to derive greater benefit from the treatment. Each case is assessed on an individual basis, and is not a process the Government can seek to influence.

Until the evidence base improves, prescribers will remain reticent in prescribing, and no decision can be made by the NHS on routine funding. That is why the Government is committed to research and catalysing the generation of evidence to support use of these products.

Like any other area of medicine, manufacturers of these products must invest in research and clinical trials to ensure that cannabis-based medicines are proven both safe and effective before they can be considered for routine funding by the NHS. The NIHR remains open to receiving good quality proposals for research in this area as a priority, and stands ready to support researchers and manufacturers to develop applications.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will hold discussions with the Lancashire Teaching Hospital Trust on the potential merits of enabling clinicians to prescribe unlicensed cannabis products to children for clinical reasons.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) has published technology appraisals recommending Epidyolex, a licensed form of cannabidiol extracted from cannabis, for the treatment of seizures associated with two rare forms of epilepsies, specifically Dravet syndrome and Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Deciding whether to prescribe an unlicensed cannabis-based medicine, a medicine that has not been assessed or approved by the medicines regulator, is a clinical decision, and the funding of medicines within the National Health Service is governed by well-established processes and evidence-based guidelines produced by the NICE. The NICE found that there is insufficient evidence of safety and effectiveness to support a population-wide recommendation in relation to unlicensed cannabis-based medicines for severe treatment-resistant epilepsy. The NICE also calls for further research.

Following the publication of the NICE’s guidance, NHS England and The National Institute for Health and Care Research (NIHR) has agreed funding for two trials relating to the use of cannabis-based medicines for the treatment of difficult-to-treat epilepsies. These will be world-first trials and will be crucial in informing future NHS funding decisions. Due to commercial confidentiality, further information on the trials cannot be released at this time.

Where a treatment is not currently routinely funded by the NHS in England, an NHS clinician can, on behalf of their patient, make an application for funding in exceptional clinical circumstances. This is known as an Individual Funding Request (IFR). In making an application for an IFR, clinicians must demonstrate that the patient in question is clinically exceptional compared to the wider group of patients with the same condition, and is likely to derive greater benefit from the treatment. Each case is assessed on an individual basis, and is not a process the Government can seek to influence.

Until the evidence base improves, prescribers will remain reticent in prescribing, and no decision can be made by the NHS on routine funding. That is why the Government is committed to research and catalysing the generation of evidence to support use of these products.

Like any other area of medicine, manufacturers of these products must invest in research and clinical trials to ensure that cannabis-based medicines are proven both safe and effective before they can be considered for routine funding by the NHS. The NIHR remains open to receiving good quality proposals for research in this area as a priority, and stands ready to support researchers and manufacturers to develop applications.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has undertaken recent research on the use of medical cannabis for the treatment of (a) Dravet and (b) Lennox-Gastaut syndrome.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) has published technology appraisals recommending Epidyolex, a licensed form of cannabidiol extracted from cannabis, for the treatment of seizures associated with two rare forms of epilepsies, specifically Dravet syndrome and Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Deciding whether to prescribe an unlicensed cannabis-based medicine, a medicine that has not been assessed or approved by the medicines regulator, is a clinical decision, and the funding of medicines within the National Health Service is governed by well-established processes and evidence-based guidelines produced by the NICE. The NICE found that there is insufficient evidence of safety and effectiveness to support a population-wide recommendation in relation to unlicensed cannabis-based medicines for severe treatment-resistant epilepsy. The NICE also calls for further research.

Following the publication of the NICE’s guidance, NHS England and The National Institute for Health and Care Research (NIHR) has agreed funding for two trials relating to the use of cannabis-based medicines for the treatment of difficult-to-treat epilepsies. These will be world-first trials and will be crucial in informing future NHS funding decisions. Due to commercial confidentiality, further information on the trials cannot be released at this time.

Where a treatment is not currently routinely funded by the NHS in England, an NHS clinician can, on behalf of their patient, make an application for funding in exceptional clinical circumstances. This is known as an Individual Funding Request (IFR). In making an application for an IFR, clinicians must demonstrate that the patient in question is clinically exceptional compared to the wider group of patients with the same condition, and is likely to derive greater benefit from the treatment. Each case is assessed on an individual basis, and is not a process the Government can seek to influence.

Until the evidence base improves, prescribers will remain reticent in prescribing, and no decision can be made by the NHS on routine funding. That is why the Government is committed to research and catalysing the generation of evidence to support use of these products.

Like any other area of medicine, manufacturers of these products must invest in research and clinical trials to ensure that cannabis-based medicines are proven both safe and effective before they can be considered for routine funding by the NHS. The NIHR remains open to receiving good quality proposals for research in this area as a priority, and stands ready to support researchers and manufacturers to develop applications.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has undertaken recent research on the use of medical cannabis for the treatment of epilepsy.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) has published technology appraisals recommending Epidyolex, a licensed form of cannabidiol extracted from cannabis, for the treatment of seizures associated with two rare forms of epilepsies, specifically Dravet syndrome and Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Deciding whether to prescribe an unlicensed cannabis-based medicine, a medicine that has not been assessed or approved by the medicines regulator, is a clinical decision, and the funding of medicines within the National Health Service is governed by well-established processes and evidence-based guidelines produced by the NICE. The NICE found that there is insufficient evidence of safety and effectiveness to support a population-wide recommendation in relation to unlicensed cannabis-based medicines for severe treatment-resistant epilepsy. The NICE also calls for further research.

Following the publication of the NICE’s guidance, NHS England and The National Institute for Health and Care Research (NIHR) has agreed funding for two trials relating to the use of cannabis-based medicines for the treatment of difficult-to-treat epilepsies. These will be world-first trials and will be crucial in informing future NHS funding decisions. Due to commercial confidentiality, further information on the trials cannot be released at this time.

Where a treatment is not currently routinely funded by the NHS in England, an NHS clinician can, on behalf of their patient, make an application for funding in exceptional clinical circumstances. This is known as an Individual Funding Request (IFR). In making an application for an IFR, clinicians must demonstrate that the patient in question is clinically exceptional compared to the wider group of patients with the same condition, and is likely to derive greater benefit from the treatment. Each case is assessed on an individual basis, and is not a process the Government can seek to influence.

Until the evidence base improves, prescribers will remain reticent in prescribing, and no decision can be made by the NHS on routine funding. That is why the Government is committed to research and catalysing the generation of evidence to support use of these products.

Like any other area of medicine, manufacturers of these products must invest in research and clinical trials to ensure that cannabis-based medicines are proven both safe and effective before they can be considered for routine funding by the NHS. The NIHR remains open to receiving good quality proposals for research in this area as a priority, and stands ready to support researchers and manufacturers to develop applications.

Found: after parties at 4am with excessive noise, ringing the doorbell at 4am, 4 night a week, cocaine and cannabis

Found: “Hemp” is a variety of cannabis with “low-THC” levels, which is currently defined as a maximum of 0.2%

Found: Four in ten had used crack cocaine (41%) and cannabis (40%), and a third had used heroin/opiat es (34%

Found: Four in ten (42 per cent) had taken crack cocaine and four in ten (42 per cent) had used cannabis.

Found: Four in ten had used crack cocaine (41 %) and cannabis (40 % ), and a third had used heroin/opiates

Found: drug dependence 30% 0.047* Drugs used in past three months Crack cocaine 37% <0.001* Cannabis

Found: Both hemp and traditional herbal cannabis are derived from the plant species Cannabis sativa L .

Found: Cannabis cultivation and labour exploitation were the most prevalent forms of exploitation (both 33%

Found: /07/2021, 13:27:34] ~ Alison Strath: Monoclonal antibodies, immunoglobulins, and wait for it …………..cannabis

Found: Thanks[09/02/2020, 15:19:20] ~ Elinor Mitchell: Sorry to bother folk - call from comms about medicinal cannabis

Found: drugs (complete self- assessment form to find out more) Do you smoke, use anu substances including cannabis

Found: (complete self - assessment form to find out more) ➢ Do you smoke, use anu substances including cannabis